The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 11.54 — safe zoneOK
Leadership changes
From Spyre Therapeutics, Inc.'s own filings, the day they're filed.
- Sandra Milligan · director · appointmenteff. 2024-05-14
- Alison Lawton · Directors · departureeff. 2024-02-01
- Mark McKenna · Chief Investment Officer · departureeff. 2024-02-01
Latest filings
- 8-K · Company announcement2026-08-25
- 8-K · Company announcement2026-08-04
- 10-Q · Quarterly report2026-08-04
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-06-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Spyre Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Spyre Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.